A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

Clinical trial NCT02205333 · TERMINATED

Trial details

NCT number: NCT02205333
Sponsor: MedImmune LLC
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors Aggressive B-cell Lymphomas

Start date: 2014-08-13
Primary completion: 2016-04-08
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.